Combined treatment with local thermo-chemotherapy for non muscle invasive bladder cancer. the present role in the light of acquired data and preliminary cumulative clinical experiences

Archivio Italiano di Urologia e Andrologia

Volumn 80, Issue 4, 2008, Pages 149-156

  Colombo, Renzo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Intravesical chemotherapy; Local hyperthermia; Non muscle invasive bladder cancer

Indexed keywords

ALPHA2B INTERFERON; APAZIQUONE; BCG VACCINE; BLEOMYCIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; MITOMYCIN C; THIOTEPA;

ALTERNATIVE MEDICINE; BCG VACCINATION; BLADDER CANCER; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CARCINOMA IN SITU; CLINICAL ASSESSMENT; CLINICAL TRIAL; CYSTECTOMY; DRUG ADSORPTION; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; HIGH RISK POPULATION; HUMAN; HYPERTHERMIC THERAPY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; RECURRENT CANCER; REVIEW; TRANSURETHRAL RESECTION; URETHRAL CATHETER;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTHERMIA, INDUCED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 58849162745     PISSN: 11243562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Clobocan 2000. Int J Cancer, 2001, 94:153-156.
2. Negri E, La Vecchia C. Epidemiology and prevention of bladder cancer. Eur J Cancer Prev. 2001, 10:7-12.
3. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49:466-477.
4. Hahn GM, Li GC. Interaction of hyperthermia and drugs: treatments and probes. Natl Cancer Inst Monogr 1982, 61:317-323.
5. Hahn GM. Potential for therapy of drigs and hyperthermia. Cancer Res 1979, 39:2264-2269.
6. Marmor JB. Interaction of hypethermia and chemotherapy in animals. Cancer Res, part 2,1979, 39:2269-2274.
7. Roizin-Towle L, Hall E], Capuano L. Interaction of hyperthermia and cytotoxic agents. Natl Cancer Inst Monogr, 1982, 61:149-155.
8. Nakajima K and Hisazumi H. Enhanced radioinduced cytotoxicity of cultured human bladder cancer cell using 43 degrees C hyperthermia or anticancer drugs. Urol Res, 1987, 15:255-261.
9. Overgaard J. The rationale for clinical trials. In Practical aspects of Clinical Hyperthermia. Edited by Field SB and Hand JW. London: taylor and Francis 1990, pp 213-241.
10. van der Heijden AG, Jansen CF, Verhaegh G, O'donnell MA, Schalken JA, Witjes JA. The effect oh hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines. Eur Urol 2004; 46(5):670-674.
11. van der Heijden AG, Verhaegh G, Jansen CF, Schalken JA, Witjes JA. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma. J Urol 2005; 173(4):1375-1380.
12. Mauroy B, Bonnal JL, Prevost B, Chve M, Lhotellier V, Sozanski JP, Vanseymortier L, Stefaniak X. Study of the synergy of microwave hyperthermia/intravesical chemotherapy in the prevention of recurrences of superficial tumors of the bladder. Prog Urol, 1999; 9(l):69-80.
13. LRath-Wolfson, B.Moskovitz, Y.Dekel, V.Kugel, R. Koren Combined intravesical hyperthermia and mitomycin C chemotherapy: a preliminary in vivo study. Int.J.Exp.Path. 2003; 84, 145-152.
14. A.van der Heijden, C.A. Hulsbergen, Van de KaaJ.A.Witjes The influence of thermo-chemoterapy on bladder tumors: an immuno-histochemical analysis. World J Urol 2007; 25:303-308.
15. Colombo R, Da Pozzo IF, Salonia A, Rigatti P, Leib Z, Baniel J, Caldarera E, Pavone-Macaluso M. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003 Dec 1; 21 (23):4270-6.
16. Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, Witjes JA, van der Heijden AG, Naspro R, Colombo R. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology. 2004 Mar; 63(3):466-71.
17. Colombo R, Salonia A, Da Pozzo LF, Naspro R, Freschi M, Paroni R, Pavone-Macaluso M, Rigatti P Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience. Crit Rev Oncol Hematol. 2003 Aug; 47(2):127-39.
18. Moskovitz B, Meyer G, Kravtzov A, Gross M, Kastin A, Biton K, Nativ O. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol. 2005 Apr; 16(4):585-9.
19. van der Heijden AG, Kiemeney LA, Gofrit ON, Nativ 0, Sidi A, Leib Z, Colombo R, Naspro R, Pavone M, Baniel J, Hasner F, Witjes JA. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol. 2004 Jul; 46(1):65-71.
20. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000 Mar; 163(3):761-7.
21. Malmström PU, Wijkström H, Lundholm C, Wester K, Busch C, Norlén BJ. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol. 1999 Apr; 161 (4):1124-7.
22. Orsola A, Palou J, Xavier B, Algaba F, Salvador J, Vicente J. Primary bladder carcinoma in situ: assessment of early BCG response as a prognostic factor. Eur Urol. 1998; 33(5):457-63.
23. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol. 2001 Oct; 166(4):1300-4.
24. Kim JC, Steinberg GD. Medical management of patients with refractory carcinoma in situ of the bladder. Drugs Aging. 2001; 18(5):335-44.
25. Witjes ]A. Bladder carcinoma in situ in 2003: state of the art. Eur Urol. 2004 Feb; 45(2):142-6.
26. Rigatti P Lev A, Colombo R. Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study. Eur Urol. 1991; 20(3):204-10.
27. M, Gallus G, Rigatti P. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol. 1996 Apr; 155(4):1227-32.
28. Colombo R, Da Pozzo LF, Lev A, Salonia A, Rigatti P, Leib Z, Servadio C, Caldarera E, Pavone-Macaluso M. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors. J Urol. 1998 Mar; 159(3):783-7.
29. Paroni R, Salonia A, Lev A, Da Pozzo LF, Cighetti G, Montorsi F, Rigatti P, Colombo R. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol. 2001 Sep; 52(3):273-8.